keyword
MENU ▼
Read by QxMD icon Read
search

Radioembolization

keyword
https://www.readbyqxmd.com/read/28323121/the-treatment-of-intermediate-stage-tumour-beyond-tace-from-surgery-to-systemic-therapy
#1
REVIEW
Peter R Galle, Francesco Tovoli, Friedrich Foerster, Marcus A Wörns, Alessandro Cucchetti, Luigi Bolondi
Intermediate stage hepatocellular carcinoma (HCC) comprises the largest subgroup of patients with this disease and is characterized by substantial heterogeneity. Functional liver impairment, total tumour burden and other prognostic factors such as high alpha-fetoprotein serum level, presence of micro-vascular invasion, and poorly differentiated tumours relevantly contribute to outcome. The usage of the standard therapeutic approach, transarterial chemoembolization - TACE, for all intermediate stage HCC patients is probably an over-simplification and may therefore not be appropriate for all patients...
March 17, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28317063/prognostic-value-of-pretreatment-diffusion-weighted-magnetic-resonance-imaging-for-outcome-prediction-of-colorectal-cancer-liver-metastases-undergoing-90y-microsphere-radioembolization
#2
Frederic Carsten Schmeel, Birgit Simon, Julian Alexander Luetkens, Frank Träber, Carsten Meyer, Leonard Christopher Schmeel, Amir Sabet, Samer Ezziddin, Hans Heinz Schild, Dariusch Reza Hadizadeh
PURPOSE: To investigate the clinical potential of pretreatment apparent diffusion coefficient (ADC) on diffusion-weighted magnetic resonance imaging (DWI) for therapy response and outcome prediction in patients with liver-predominant metastatic colorectal cancer (CRC) undergoing radioembolization with (90)Yttrium-microspheres (90Y-RE). METHODS: Forty-six consecutive patients with unresectable CRC liver metastases underwent standardized clinical DWI on a 1.5 T MR scanner prior to and 4-6 weeks after 90Y-RE...
March 19, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28300366/internal-dosimetry-for-radioembolization-therapy-with-yttrium-90-microspheres
#3
Maryam Fallahpoor, Mehrshad Abbasi, Ali Asghar Parach, Faraz Kalantari
The absorbed doses in the liver and adjacent viscera in Yttrium-90 radioembolization therapy for metastatic liver lesions are not well-documented. We sought for a clinically practical way to determine the dosimetry of this advent treatment. Six different female XCAT BMIs and seven different male XCAT BMIs were generated. Using Monte Carlo GATE code simulation, the total of 100MBq (90) Y was deposited uniformly in the source organ, liver. Self-irradiation and absorbed doses in lung, kidney and bone marrow were calculated...
March 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28299645/new-concepts-in-embolotherapy-of-hcc
#4
REVIEW
F Pesapane, N Nezami, F Patella, J F Geschwind
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide with rapidly growing incidence rates in the USA and Europe. Despite improving surveillance programs, most patients are diagnosed at intermediate to advanced stages and are no longer amenable to curative therapies, such as ablation, surgical resection and liver transplantation. For such patients, catheter-based image-guided embolotherapies such as transarterial chemoembolization (TACE) represent the standard of care and mainstay therapy, as recommended and endorsed by a variety of national guidelines and staging systems...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28292478/real-world-data-for-the-evaluation-of-transarterial-radioembolization-versus-sorafenib-in-hepatocellular-carcinoma-a-cost-effectiveness-analysis
#5
Carla Rognoni, Oriana Ciani, Silvia Sommariva, Rosanna Tarricone
OBJECTIVES: To perform a cost-effectiveness analysis comparing the use of transarterial radioembolization (TARE) with that of sorafenib in the treatment of patients with intermediate or advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system. METHODS: Patient-level data were consecutively recorded and collected at three oncology centers in Italy. A propensity score matching was performed to compare patients with similar clinical characteristics who underwent TARE or sorafenib treatment...
March 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28283704/cytokines-and-90-y-radioembolization-relation-to-liver-function-and-overall-survival
#6
Max Seidensticker, Maciej Powerski, Ricarda Seidensticker, Robert Damm, Konrad Mohnike, Benjamin Garlipp, Maurice Klopffleisch, Holger Amthauer, Jens Ricke, Maciej Pech
BACKGROUND: To evaluate the course of pro- and anti-inflammatory cytokines after (90)Y-radioembolization (RE) of liver malignancies and to identify prognosticators for liver-related adverse events and survival. METHODS: In 34 consecutive patients with secondary or primary liver tumors scheduled for RE, the following cytokines were measured prior to and 2 h, 3 days, and 6 weeks after RE: interleukin (IL) -1, IL-2, IL-4, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), and interferon-γ...
March 10, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28280611/baseline-hemoglobin-and-liver-function-predict-tolerability-and-overall-survival-of-patients-receiving-radioembolization-for-chemotherapy-refractory-metastatic-colorectal-cancer
#7
Andrew S Kennedy, David Ball, Steven J Cohen, Michael Cohn, Douglas M Coldwell, Alain Drooz, Edward Ehrenwald, Samir Kanani, Fred M Moeslein, Charles W Nutting, Samuel G Putnam, Steven C Rose, Michael Savin, Sabine Schirm, Navesh K Sharma, Eric Wang
BACKGROUND: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving (90)Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liver-directed radiation, standard laboratory tests may assist in improving outcome by identifying correctable pre-radiation abnormalities. METHODS: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used...
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28268101/downstaging-of-bilobar-hepatocellular-carcinoma-after-radioembolization-with-90-y-microspheres-as-a-bridge-to-liver-transplantation
#8
L Reguera-Berenguer, J Orcajo-Rincón, A Rotger-Regí, A M Matilla-Peña, M Echenagusia-Boyra, R Pérez-Pascual, A Marí-Hualde, J C Alonso-Farto
Hepatic radioembolization with (90)Y is an increasingly widely used locoregional therapy in the treatment of hepatocellular carcinoma. Its potential benefit has recently been described as a downstaging treatment, achieving a decreased tumour burden and allowing patients to be rescued for more radical treatments, such as liver transplantation. The case is presented of a patient diagnosed with multifocal bilobar hepatocellular carcinoma, Barcelona Clinic Liver Cancer (BCLC) intermediate stage, in whom treatment with (90)Y achieved a satisfactory radiological response with a very significant reduction of tumour burden, allowing rescue with liver transplantation...
March 3, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28261595/commentary-on-the-article-entitled-hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#9
Wan Yee Lau
No abstract text is available yet for this article.
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28261594/hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#10
Giovanni Battista Levi Sandri, Giuseppe Maria Ettorre, Marco Colasanti, Edoardo De Werra, Gianluca Mascianà, Daniele Ferraro, Giovanni Tortorelli, Rosa Sciuto, Pierleone Lucatelli, Giuseppe Pizzi, Ubaldo Visco-Comandini, Giovanni Vennarecci
BACKGROUND: Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure. METHODS: From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28261591/intra-arterial-embolotherapy-for-intrahepatic-cholangiocarcinoma-update-and-future-prospects
#11
REVIEW
Lynn Jeanette Savic, Julius Chapiro, Jean-François H Geschwind
Intrahepatic cholangiocarcinoma (ICC) is a rare disease and carries a poor prognosis with surgery remaining the only curative treatment option. However, due to the late presentation of symptoms and close proximity of the tumors to central hepatic structures, only about 30% of patients are classified eligible to resection. As for palliative approaches, ICC constitutes a possible indication for loco-regional therapies (LRT). As such, intra-arterial therapies (IAT) are reported to be feasible, safe and effective in inducing tumor response in unresectable ICC...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28240669/90-y-liver-radioembolization-imaging-using-amplitude-based-gated-pet-ct
#12
Dustin R Osborne, Shelley Acuff, Melissa Neveu, Austin Kaman, Mumtaz Syed, Yitong Fu
The usage of PET/CT to monitor patients with hepatocellular carcinoma following Y radioembolization has increased; however, image quality is often poor because of low count efficiency and respiratory motion. Motion can be corrected using gating techniques but at the expense of additional image noise. Amplitude-based gating has been shown to improve quantification in FDG PET, but few have used this technique in Y liver imaging. The patients shown in this work indicate that amplitude-based gating can be used in Y PET/CT liver imaging to provide motion-corrected images with higher estimates of activity concentration that may improve posttherapy dosimetry...
February 24, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28238581/correlation-of-technetium-99m-macroaggregated-albumin-and-yttrium-90-glass-microsphere-biodistribution-in-hepatocellular-carcinoma-a-retrospective-review-of-pretreatment-single-photon-emission-ct-and-posttreatment-positron-emission-tomography-ct
#13
Paul Haste, Mark Tann, Scott Persohn, Thomas LaRoche, Vasantha Aaron, Thibault Mauxion, Nikhil Chauhan, Matthew R Dreher, Matthew S Johnson
PURPOSE: To evaluate whether technetium-99 ((99m)Tc)-labeled macroaggregated albumin (MAA) can predict subsequent yttrium-90 ((90)Y) distribution and imaging response in patients with hepatocellular carcinoma (HCC). MATERIALS: Retrospective review was performed of records of 83 patients with HCC who underwent (90)Y glass microsphere radioembolization with (99m)Tc-MAA single photon emission computed tomography (SPECT) and (90)Y positron emission tomography (PET)/CT between January 2013 and December 2014...
February 23, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28229076/locoregional-therapies-of-cholangiocarcinoma
#14
REVIEW
Christof M Sommer, Hans U Kauczor, Philippe L Pereira
BACKGROUND: Cholangiocarcinoma (CC) is the second most primary liver malignancy with increasing incidence in Western countries. Currently, surgical R0 resection is regarded as the only potentially curative treatment. The results of systemic chemotherapy and best supportive care (BSC) in patients with metastatic disease are often disappointing in regard to toxicity, oncologic efficacy, and overall survival. In current practice, the use of different locoregional therapies is increasingly more accepted...
December 2016: Visceral Medicine
https://www.readbyqxmd.com/read/28206962/pi3k-pathway-mutations-are-associated-with-longer-time-to-local-progression-after-radioembolization-of-colorectal-liver-metastases
#15
Etay Ziv, Michael Bergen, Hooman Yarmohammadi, F Ed Boas, E Nadia Petre, Constantinos T Sofocleous, Rona Yaeger, David B Solit, Stephen B Solomon, Joseph P Erinjeri
PURPOSE: To establish the relationship between common mutations in the MAPK and PI3K signaling pathways and local progression after radioembolization. MATERIALS AND METHODS: Retrospective review of a HIPAA-compliant institutional review-board approved database identified 40 patients with chemo-refractory colorectal liver metastases treated with radioembolization who underwent tumor genotyping for hotspot mutations in 6 key genes in the MAPK/PI3K pathways (KRAS, NRAS, BRAF, MEK1, PIK3CA, and AKT1)...
February 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#16
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28196771/liver-metastases-from-breast-cancer-what-role-for-surgery-indications-and-results
#17
REVIEW
Nicolas Golse, René Adam
Liver metastases from breast cancer (LMBC) have long been considered as a systemic disease because of the hematological route of dissemination, requiring noncurative management. In fact, despite recent advances in drug therapies personalized to tumor phenotype, the chances of a cure are nil and there is little hope of long-term survivors after nonsurgical management alone. By contrast, there is a growing evidence in the literature for satisfactory long-term results after a combination of chemotherapy and liver resection, with 5-year survival reaching >40% in some series...
January 9, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28190710/neutrophil-to-lymphocyte-ratio-predicts-disease-progression-following-intra-arterial-therapy-of-hepatocellular-carcinoma
#18
Matthew D Taussig, Mary Ellen Irene Koran, Samdeep K Mouli, Asma Ahmad, Sunil Geevarghese, Jennifer C Baker, Andrew J Lipnik, Fil Banovac, Daniel B Brown
BACKGROUND: Prospectively predicting response to intra-arterial therapy for hepatocellular carcinoma (HCC) is challenging. Neutrophil/lymphocyte ratio (NLR) is a serum biomarker that is associated with survival for multiple malignancies. It was hypothesized that increased NLR would be associated with early disease progression after intra-arterial therapy of HCC. METHODS: The outcomes of 86 treatment-naïve patients who had chemoembolization or radioembolization of HCC between July 2013-July 2014 were reviewed...
February 9, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/28179284/the-evolving-role-of-local-treatments-for-hcc-in-the-third-millennium
#19
REVIEW
Paolo Magistri, Giuseppe Tarantino, Roberto Ballarin, Massimiliano Berretta, Annarita Pecchi, Giovanni Ramacciato, Fabrizio DI Benedetto
BACKGROUND: Hepatocellular carcinoma (HCC) represents the fifth most common malignancy and the third cancer-related cause of death worldwide. The aim of this review was to clarify the role of local treatments for HCC, analyzing the indications and defining future perspectives. MATERIALS AND METHODS: A systematic literature search was performed independently by two of the authors according to the PRISMA statement guidelines. The search was limited to studies reported in English between January 2005 and June 2016...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28154910/value-of-tumor-stiffness-measured-with-mr-elastography-for-assessment-of-response-of-hepatocellular-carcinoma-to-locoregional-therapy
#20
Sonja Gordic, Jad Bou Ayache, Paul Kennedy, Cecilia Besa, Mathilde Wagner, Octavia Bane, Richard L Ehman, Edward Kim, Bachir Taouli
PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA). MATERIAL AND METHODS: This retrospective study was IRB-approved and the requirement for informed consent was waived...
February 2, 2017: Abdominal Radiology
keyword
keyword
13605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"